Payment overview · 2025
General Payments
$178.69
9 reported records · 9 companies
Healthcare provider profile · identity verified
James V Ortman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OMAHA, NE · NPI 1154423085
Verified facts
What the public records show
CMS Open Payments records show James V Ortman, MD received $178.69 in general payments during 2025 across 9 reported records.
Inspire Medical Systems, Inc. accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 388 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $37.65 | 21.1% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.11 | 13.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.24 | 11.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.28 | 9.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $16.90 | 9.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.74 | 9.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.23 | 9.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.16 | 9.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.38 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $178.69 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $37.65 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 388 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
388 | 54 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 612 | 149 |
| Levothyroxine Sodium | Levothyroxine Sodium | 423 | 63 |
| Eliquis | Apixaban | 388 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 379 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 304 | 66 |
| Lisinopril | Lisinopril | 284 | 80 |
| Simvastatin | Simvastatin | 193 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 45 |
| Metformin Hcl | Metformin Hcl | 181 | 44 |
| Omeprazole | Omeprazole | 168 | 43 |
| Losartan Potassium | Losartan Potassium | 165 | 48 |
| Alprazolam | Alprazolam | 148 | 30 |
| Gabapentin | Gabapentin | 138 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 128 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 25 |
| Furosemide | Furosemide | 115 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 113 | 31 |
| Potassium Chloride | Potassium Chloride | 113 | 28 |
| Myrbetriq | Mirabegron | 103 | 12 |
| Sertraline Hcl | Sertraline Hcl | 100 | 28 |
| Trazodone Hcl | Trazodone Hcl | 90 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 16 |
| Donepezil Hcl | Donepezil Hcl | 77 | 14 |
| Alendronate Sodium | Alendronate Sodium | 76 | 12 |
| Mirtazapine | Mirtazapine | 75 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 13 |
| Finasteride | Finasteride | 68 | 14 |
| Memantine Hcl | Memantine Hcl | 68 | suppressed |
| Ozempic | Semaglutide | 68 | 13 |
| Allopurinol | Allopurinol | 66 | 16 |
| Latanoprost | Latanoprost | 63 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 16 |
| Famotidine | Famotidine | 59 | 15 |
| Jardiance | Empagliflozin | 52 | suppressed |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 50 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 48 | 15 |
| Celecoxib | Celecoxib | 46 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 17 |
| Prednisone | Prednisone | 46 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | 12 |
| Carvedilol | Carvedilol | 41 | 14 |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Meloxicam | Meloxicam | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Galantamine Er | Galantamine Hbr | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Methadone Hcl | Methadone Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Riluzole | Riluzole | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $178.69 · 9 records | Inspire Medical Systems, Inc. | Cologuard Collection Kit, ELIQUIS, GVOKE HYPOPEN, INSPIRE, JARDIANCE, NURTEC ODT, Ozempic, TZIELD, VOQUEZNA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error